FibroBiologics, a clinical-stage biotech company, now holds 170 issued patents and over 325 patents issued and pending worldwide related to fibroblast-based therapies. This extensive intellectual property portfolio covers therapeutic uses across multiple diseases and manufacturing methods, solidifying FibroBiologics as a global leader in fibroblast cell therapy. The patents include treatments for conditions like wound healing, diabetes, osteoporosis, and cancer, as well as innovations in production techniques. This strong IP position enables FibroBiologics to continue investing in developing new therapies and partnering with others to bring these treatments to patients.
FibroBiologics' intellectual property update is presented here with Pluang's Health-sector market data as of Nov 12, 2026 20:12 WIB. Of 150 priced Health-sector US stocks tradable on Pluang, 82 rose and 64 fell today. Notable movers include INO at USD 1.42 with a 1-day change of -3.73%, MRNA at USD 239.52 down 3.69%, and RXRX at USD 3.46 down 3.62%, with RXRX showing 100% buy order activity on Pluang.
Interlink Electronics announced a 3.4% revenue increase to $3.06 million for Q3 2026 and a 9.6% rise to $9.9 million for the first nine months of 2026, driven by higher shipments of force-sensing and gas-sensor products. The company reported a net lo...
ALS Canada, with renewed funding from TD Bank, is advancing its national strategy for ALS genetics to enhance access to genetic information, counselling, and care for Canadians affected by or at risk of ALS. This builds on the 2024 pilot of the first...
The Canadian ALS Society has renewed funding from TD Bank to expand its national genetics strategy for ALS, improving access to genetic information, counseling, and care for those affected or at risk. This initiative builds on a pilot project that cr...
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
